461 (Carbidopa and levodopa extended release 25 mg / 100 mg)
Pill imprint 461 has been identified as Carbidopa and levodopa extended release 25 mg / 100 mg.
Carbidopa/levodopa is used in the treatment of parkinson's disease; restless legs syndrome; neuroleptic malignant syndrome; gtp-ch deficiency and belongs to the drug class dopaminergic antiparkinsonism agents. Risk cannot be ruled out during pregnancy. Carbidopa/levodopa 25 mg / 100 mg is not subject to the Controlled Substances Act.
See also related documents.
Images for 461 (Carbidopa and levodopa extended release 25 mg / 100 mg)
More about carbidopa/levodopa
- Carbidopa/levodopa orally disintegrating tablets
- Carbidopa/levodopa sustained-release tablets
- Carbidopa and levodopa